表柔比星联合卡铂治疗乳腺癌的临床研究  

Epirubicin in combination with carboplatin in the treatment of breast cancer

作　　者：孙二虎 周茜[1] 刘小丰[1] SUN Er-hu;ZHOU Qian;LIU Xiao-feng(Maternal and Obstetric Hospital Affiliated to Nanjing Medical University/Nanjing Maternal and Child Health Hospital,Department of Breast,Nanjing 210000,Jiangsu Province,China)

机构地区：[1]南京医科大学附属妇产医院/南京市妇幼保健院乳腺科,江苏南京210000

出　　处：《中国临床药理学杂志》2020年第12期1625-1627,1634,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察表柔比星联合卡铂治疗乳腺癌的临床疗效及安全性。方法将乳腺癌患者100例随机分为对照组49例和试验组51例。对照组予以静脉滴注卡铂25 mg·m^-2;试验组在对照组的基础上给予静脉滴注表柔比星60 mg·m^-2。2组每次给药持续30 min,每日1次,21 d为1周期,治疗4个周期。比较2组患者的临床疗效、血清多巴胺(DA)、乳腺癌相关肽(TFF1)和肿瘤坏死因子-α(TNF-α)、血管内皮生长因子(VEGF)、基质金属蛋白酶9(MMP-9)的水平,以及药物不良反应发生率。结果治疗后,试验组和对照组的总有效率分别为86.27%(44例/51例)和65.31%(32例/49例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组血清DA分别为(168.65±21.13)和(135.41±21.14)pg·mL^-1;TFF1分别为(95.79±10.31)和(71.23±11.13)pg·mL^-1;TNF-α分别为(204.51±42.43)和(176.84±35.16)ng·L^-1;VEGF分别为(69.34±11.35)和(103.52±15.36)ng·mL^-1;MMP-9分别为(33.21±4.73)和(55.27±4.39)ng·mL^-1,差异均有统计学意义(均P<0.05)。试验组和对照组的药物不良反应发生率分别为21.57%(11例/51例)和46.94%(23例/49例),差异有统计学意义(P<0.05)。结论表柔比星治疗乳腺癌效果显著,可有效改善血清DA、TFF1及血清细胞因子水平,且安全性较好。Objective To study clinical efficacy and safetyness of epirubicin in treatment of breast cancer.Methods 100 cases of breast cancer were randomly divided into control group(49 cases)and experimental group(51 cases).The control group was given 25 mg·m^-2 carboplatin by intravenous infusion.The treatment group was given epirubicin 60 mg·m^-2 on the basis of the control group.Both groups were treated 30 min once daily,21 d for 1 cycle,and the treatment lasted for 4 cycles.The clinical efficacy,serum dopamine(DA),breast cancer-related peptide(TFF1)and tumor necrosis factor-alpha(TNF-α),vascular endothelial growth factor(VEGF),matrix metalloproteinase 9(MMP-9),and the incidence of adverse drug reactions in the two groups were compared.Results After treatment,the total effective rates of the experimental group and control group were 86.27%(44 cases/51 cases)and 65.31%(32 cases/49 cases),respectively,with statistically significant differences(P<0.05).After treatment,serum DA was(168.65±21.13)and(135.41±21.14)pg·mL^-1,TFF1 was(95.79±10.31)and(71.23±11.13)pg·mL^-1,tnf-alpha was(204.51±42.43)and(176.84±35.16)ng·L^-1,and VEGF was(69.34±11.35)and(103.52±15.36)ng·mL^-1,respectively.MMP-9 was(33.21±4.73)and(55.27±4.39)ng·mL^-1,respectively,with statistically significant differences(all P<0.05).The incidence of total adverse reactions in the test group and control group were 21.57%and 46.94%,respectively,with statistically significant differences(P<0.05).Conclusion Epirubicin has a significant effect in the treatment of breast cancer and can effectively improve serum DA,TFF1 and serum cytokine levels,with few adverse drug reactions.

关 键 词：表柔比星 乳腺癌 多巴胺 乳腺癌相关肽 细胞因子 

分 类 号：R979.1[医药卫生—药品]